• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC

byAlisha YiandMinjee Kim
December 14, 2023
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Median PFS and OS between the tiragolumab and control arms were similar

2. Treatment-related AEs that were grade 3/4 occurred in 52.7% in the tiragolumab arm and 55.7% in the control arm.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Extensive-stage small-cell lung cancer (ES-SCLC) is currently treated with atezolizumab/carboplatin/etoposide or durvalumab/chemotherapy, however, most patients have poor median survival. Tiragolumab, an antibody targeting T-cell immunoreceptor with Ig and ITIM domains (TIGIT), has shown antitumor activity. This study evaluated the addition of tiragolumab to atezolizumab/carboplatin/etoposide in untreated ES-SCLC patients. The primary endpoints were progression-free survival (PFS) and overall survival (OS), and secondary endpoints included objective response rate (ORR), duration of response (DoR), and safety. Median PFS was 5.1 months in the tiragolumab group vs 5.4 months in the control group, with HR 1.08, with similar results in a sub-group analysis in patients without brain metastases. PFS at 6 and 12 months were 31.3% and 12.3% with tiragolumab and 38.0% and 14.1% with control. Median OS was 12.8 months in the tiragolumab group vs 12.9 months in the control group, with HR 1.09 (p=.4205), with similar results in a sub-group analysis in patients without brain metastases, or with patients with positive PD-L1. OS at 24 months was 21% vs 26%, respectively. ORR was 70.8% and 65.6% with tiragolumab and control, respectively, and the median DoR was 4.2 and 5.1 months. With regards to safety, treatment-related AEs (TRAEs) that were grade 3/4 occurred in 52.7% in the tiragolumab arm and 55.7% in the control arm and were most commonly anemia and neutropenia. The strengths of this study included its methodology and the inclusion of patients with brain metastasis, and the limitations included a small sample size. Overall, it was found that the addition of tiragolumab to standard treatment (atezolizumab/carboplatin/etoposide) did not improve outcomes in patients with extensive-stage small-cell lung cancer.

Click to read the study in JCO

In-Depth [randomized controlled trial]: This international phase III trial recruited adults with treatment-naïve confirmed ES-SCLC and randomized (1:1) them to tiragolumab (243 patients) vs placebo (247 patients), in addition to atezolizumab/carboplatin/etoposide. Patients with brain metastases were permitted. Median PFS was 5.1 months in the tiragolumab group vs 5.4 months in the control group, with HR 1.08 (95%CI, 0.89-1.31) with similar results in a sub-group analysis in patients without brain metastases. PFS at 6 and 12 months were 31.3% and 12.3% with tiragolumab and 38.0% and 14.1% with control. Median OS was 12.8 months in the tiragolumab group vs 12.9 months in the control group, with HR 1.09 (95%CI, 0.88-1.35, p=.4205), with similar results in a sub-group analysis in patients without brain metastases, or with patients with positive PD-L1. OS at 24 months was 21% vs 26%, respectively. ORR was 70.8% and 65.6% with tiragolumab and control, respectively, and the median DoR was 4.2 and 5.1 months. With regards to safety, TRAEs that were grade 3/4 occurred in 52.7% in the tiragolumab arm and 55.7% in the control arm and were most commonly anemia and neutropenia. Overall, it was found that the addition of tiragolumab to standard treatment (atezolizumab/carboplatin/etoposide) did not improve outcomes in patients with extensive-stage small-cell lung cancer.

RELATED REPORTS

Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC

Adebrelimab plus chemotherapy improves overall survival in extensive-stage small-cell lung cancer

Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: extensive SCLCtiragolumab
Previous Post

Traffic-related air pollution is associated with increased blood pressure

Next Post

Current expert consensus for the treatment of adult patients with drug reaction with eosinophilia and systemic symptoms

RelatedReports

Patient Basics: Lung Cancer Overview
Oncology

Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC

December 11, 2023
Patient Basics: Lung Cancer Overview
Oncology

Adebrelimab plus chemotherapy improves overall survival in extensive-stage small-cell lung cancer

May 23, 2022
Complement mutation linked to poor response to eculizumab
Oncology

Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer

May 23, 2022
Next Post
Lirentelimab may be effective for treatment of eosinophilic gastrointestinal disease

Current expert consensus for the treatment of adult patients with drug reaction with eosinophilia and systemic symptoms

#VisualAbstract: Ibrutinib-Venetoclax Improves Progression-Free Survival in Chronic Lymphocytic Leukemia

#VisualAbstract: Ibrutinib-Venetoclax Improves Progression-Free Survival in Chronic Lymphocytic Leukemia

Adolescents’ muscle strength associated with lower cardiometabolic risk

Concurrent strength and endurance training in females increases parameters associated with maximal strength and endurance capacity

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
  • #VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.